LD
MRNA icon

Lipe & Dalton’s Moderna MRNA Stock Holding History

Lipe & Dalton’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,147
Closed -$544K – 101
2024
Q3 		$544K Sell
8,147
-1,695
-17% -$156K 0.27% 63
2024
Q2 		$1.17M Sell
9,842
-655
-6% -$82.9K 0.63% 48
2024
Q1 		$1.12M Sell
10,497
-3,865
-27% -$390K 0.58% 48
2023
Q4 		$1.43M Hold
14,362
– – 0.77% 40
2023
Q3 		$1.48M Hold
14,362
– – 0.89% 37
2023
Q2 		$1.75M Sell
14,362
-5
-0% -$667 0.99% 35
2023
Q1 		$2.21M Sell
14,367
-277
-2% -$45.7K 1.26% 29
2022
Q4 		$2.63M Buy
+14,644
New +$2.39M 1.51% 23

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Lipe & Dalton's MRNA Position: Q4 2024 in Review

Lipe & Dalton sold out of Moderna (MRNA) in Q4 2024, closing a stake of 8,147 shares — an estimated $544K sold.

Lipe & Dalton first reported a position in MRNA in Q4 2022 and held it in 8 quarters. The position peaked at $2.63M in Q4 2022. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Lipe & Dalton reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Lipe & Dalton sold 8,147 Moderna shares in Q4 2024, an estimated $544K.
  • Lipe & Dalton first reported a position in Moderna in Q4 2022 and held it in 8 quarters.
  • Lipe & Dalton's Moderna position peaked at $2.63M in Q4 2022.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Lipe & Dalton's 13F filing for Q4 2024, filed 3 Feb 2025.